Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Diaceutics PLC
  6. Summary
    DXRX   GB00BJQTGV64

DIACEUTICS PLC

(DXRX)
  Report
Delayed London Stock Exchange  -  04:20:56 2023-01-31 am EST
107.40 GBX   +0.85%
01/27TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing
AN
01/26Diaceutics Secures $7 Million Subscription Data Services Contracts; Share Price Up 12%
MT
01/26Diaceutics PLC Announces Two Enterprise-Level, Multi-Disease Data Engagements
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/25/2023 01/26/2023 01/27/2023 01/30/2023 01/31/2023 Date
79(c) 96(c) 98.5(c) 106.5(c) 107.4 Last
15 440 354 226 106 687 81 692 5 092 Volume
0.00% +21.52% +2.60% +8.12% +0.85% Change
More quotes
Estimated financial data (e)
Sales 2022 20,0 M 24,7 M 24,7 M
Net income 2022 0,10 M 0,12 M 0,12 M
Net cash position 2022 19,9 M 24,6 M 24,6 M
P/E ratio 2022 205x
Yield 2022 -
Sales 2023 24,0 M 29,7 M 29,7 M
Net income 2023 -2,30 M -2,85 M -2,85 M
Net cash position 2023 15,9 M 19,7 M 19,7 M
P/E ratio 2023 -44,6x
Yield 2023 -
Capitalization 89,8 M 111 M 111 M
EV / Sales 2022 3,50x
EV / Sales 2023 3,08x
Nbr of Employees 133
Free-Float 53,1%
More Financials
Company
Diaceutics PLC is a diagnostic commercialization company. The principal activity of the Company is data analytics and implementation services. The Company is engaged in research and development activities in drug development science, testing data and software platform development. The Company's implementation services include test standardization, test quality assessment, test report optimization, laboratory tech... 
Read more
More about the company
Ratings of Diaceutics PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about DIACEUTICS PLC
01/27TRADING UPDATES: Diaceutics wins two deals; Faron proposes placing
AN
01/26Diaceutics Secures $7 Million Subscription Data Services Contracts; Share Price Up 12%
MT
01/26Diaceutics PLC Announces Two Enterprise-Level, Multi-Disease Data Engagements
CI
01/26Diaceutics PLC Reports Revenue Results for the Year Ended 31 December 2022
CI
2022TRADING UPDATES: Alternative Income assets rise; Ironveld signs deal
AN
2022Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medic..
CI
2022Transcript : Diaceutics PLC, H1 2022 Earnings Call, Sep 28, 2022
CI
2022Earnings Flash (DXRX.L) DIACEUTICS Reports H1 Revenue GBP7.5M
MT
2022Earnings Flash (DXRX.L) DIACEUTICS Reports H1 Loss GBPX-0.89
MT
2022Diaceutics PLC Reports Earnings Results for the Half Year Ended June 30, 2022
CI
2022Diaceutics PLC Announces Revenue Results for the Six Months Ended June 30, 2022
CI
2022Diaceutics PLC Announces Multi-Year Contract with Top Five Global Pharma
CI
2022Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX Platform
CI
2022Diaceutics Bags $1 Million Data Subscription Deal With Pharma Company
MT
2022Diaceutics PLC Secures Five-Year, Multi-Product Subscription Contract with A Top 30 Glo..
CI
More news
News in other languages on DIACEUTICS PLC
01/27MISES À JOUR COMMERCIALES : Diaceutics remporte deux contrats ..
01/26Diaceutics décroche des contrats de services de données par abonnement pour un montant ..
01/26Diaceutics PLC annonce deux engagements de données multi-maladies au niveau de l'entrep..
2022Diaceutics PLC annonce la publication d'une étude sur les inefficacités de la médecine ..
2022Earnings Flash (DXRX.L) DIACEUTICS annonce un chiffre d'affaires de 7,5 millions de liv..
More news
Chart DIACEUTICS PLC
Duration : Period :
Diaceutics PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 106,50 GBX
Average target price 175,00 GBX
Spread / Average Target 64,3%
EPS Revisions
Managers and Directors
Peter Keeling Chief Executive Officer & Director
Nick Roberts Chief Financial Officer & Director
Deborah Lee Davis Non-Executive Chairman
Johnny Rice Director-Information Technology
Julie Browne Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
DIACEUTICS PLC41.06%111
CLARIVATE PLC32.49%7 451
WNS (HOLDINGS) LIMITED6.75%3 980
KEHUA DATA CO., LTD.0.94%3 444
VERRA MOBILITY CORPORATION9.26%2 265
JMDC INC.15.61%2 106